**MicroRNAs in the development and neoplasia of the mammary gland [version 2; referees: 2 approved, 1 approved with reservations]**

Manoj Kumar Jena

Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University (LPU), Phagwara, Punjab, 144411, India

**Abstract**

Study on the role of microRNAs (miRs) as regulators of gene expression through posttranscriptional gene silencing is currently gaining much interest due to their wide involvement in different physiological processes. Understanding mammary gland development, lactation, and neoplasia in relation to miRs is essential. miR expression profiling of the mammary gland from different species in various developmental stages shows their role as critical regulators of development. miRs such as miR-126, miR-150, and miR-145 have been shown to be involved in lipid metabolism during lactation. In addition, lactogenic hormones influence miR expression as evidenced by overexpression of miR-148a in cow mammary epithelial cells, leading to enhanced lactation. Similarly, the miR-29 family modulates lactation-related gene expression by regulating DNA methylation of their promoters. Besides their role in development, lactation and involution, miRs are responsible for breast cancer development. Perturbed estrogen (E2) signaling is one of the major causes of breast cancer. Increased E2 levels cause altered expression of ERα, and ERα-miR cross-talk promotes tumour progression. miRs, such as miR-206, miR-34a, miR-17-5p, and miR-125 a/b are found to be tumour suppressors; whereas miR-21, miR-10B, and miR-155 are oncogenes. Oncogenic miRs like miR-21, miR-221, and miR-210 are overexpressed in triple negative breast cancer cases which can be diagnostic biomarker for this subtype of cancer. This review focuses on the recent findings concerning the role of miRs in developmental stages of the mammary gland (mainly lactation and involution stages) and their involvement in breast cancer progression. Further studies in this area will help us to understand the molecular details of mammary gland biology, as well as miRs that could be therapeutic targets of breast cancer.
Introduction

MicroRNAs (miRs) are small, endogenous noncoding RNAs that regulate gene expression post-transcription, by degrading target mRNA or repressing translation. They are hardy in nature, being resistant to RNAsase degradation, acidic pH, and repeated freezing and thawing, and are stable at room temperature. Matured miRs integrate into the RNA - induced silencing complex (RISC) and direct it to target miRNAs through partial sequence complementarity. miRs down regulate the target gene expression by translation repression (48% through RISC complex), or mRNA degradation (29%), or by both phenomena (23%). In addition to their involvement in many other physiological processes, they play crucial roles in mammary gland development and lactation, and their deregulation can lead to breast cancer. This review provides an overview on the recent findings concerning the role of miRs in the developmental stages of the mammary gland and breast cancer progression.

miRs in mammary glands

The study of miRs in mammary gland development is essential, as miRs in milk are derived from the mammary gland and can be a biomarker of a healthy lactating gland, as well as protecting infants and promoting their development.

miRs in milk during lactation are putative markers of activities in mammary gland and act as functional signals for proper growth and development of the young. The highly abundant miRs in milk during lactation cycle are miR-191, 184, 181, 148, 375, and miRs of let-7 family (7f, 7a and 7i) as evidenced from studies in the marsupial tammar wallaby. Comparative analysis of the miRNome of bovine milk, mammary tissue, milk fat, and whey revealed 188 miRs in common, with some novel miRs discovered. The miR signature of milk fat was similar to that of mammary gland tissue miRs. Functional studies of highly expressed miRs in those fractions indicated their role as regulators of mammary gland functions contributing to healthy milk production.

miRs controlling lactation

It was observed that miR-126 plays a role in mammary epithelial cells (MECs) by modulating lipid synthesis. FASN (fatty acid synthase) gene expression is increased when miR-126-3p is inhibited, suggesting its involvement in lipid metabolism in the mammary gland. In addition, estradiol and progesterone enhanced lipid synthesis by downregulating the levels of miR-126-3p. Similarly, miR-150 hampers lipogenesis in MECs and reduces secretory activity, while miR-145 facilitates milk fat synthesis in lactating goats by targeting the gene INSIG1 (insulin induced gene 1).

The role that miRs play as regulators of lipogenesis was confirmed by overexpression studies, which showed that there was more synthesis of fat droplets, accumulating triacylglycerols, and a higher proportion of unsaturated fatty acids in lactating MECs. For instance, miR-24 was found to be expressed at a much higher level during peak lactation in goats and affects triacylglycerol content, unsaturated fatty acid concentration, and expression of target genes such as FASN, SREBF1 (sterol regulatory element binding transcription factor1), SCD (stearoyl-CoA desaturase), GPAM (glycerol-3-phosphate acyltransferase; mitochondrial), and ACACA (acetyl-CoA carboxylase).

miR expression in MECs is regulated by lactogenic hormones (dexamethasone, insulin, and prolactin) as evidenced by an increased miR-148a level in bovine MECs, which is probably associated with increased milk production during lactation in cows. The miR-29 family affects lactation by regulating the DNA methylation of target genes DNMT3A and DNMT3B (DNA (cytosine-5)-methyltransferase 3A and 3B) in MECs of dairy cows. Moreover, inhibition of the miR-29 family resulted in hypermethylation of promoters of lactation–related genes leading to decreased secretion of triglycerides, proteins, and lactose by the epithelial cells. miR-486 facilitates lactation by downregulating PTEN (phosphatase and tensin homolog) target gene. Downregulation of this gene affects the expression of downstream genes, such as AKT, mTOR and β-casein, which have crucial roles in mammary gland development and lactation. Additionally, diet restriction has been shown to affect the miRNome of lactating mammary glands, indicating the role of miRs in regulating milk composition. Lin et al. (2013) observed group of miRs (such as miR-23a, 27b, 103, and 200a) affect milk fat synthesis with synergistic action. miR profiling of lactating and nonlactating bovine mammary gland revealed miR-125b, 181a, and 199b expression level reduced in non-lactation period; whereas miR-141, 484, and 500 expression level was higher in lactation period. Highly expressed miRs such as let-7f-5p is found to target many genes involved in protein, carbohydrate, and triglyceride synthesis. The human milk enriched miR such as miR-22-3P regulates development and differentiation of T-lymphocytes. The miR-181a-5p and miR-182-5p have crucial role in immune cell differentiation, miR-375 is required for glucose homeostasis, and miR-148a-3p is a tumour suppressor and involved in liver development.

miRs controlling involution and breast cancer

Identification and characterization of miRs involved in breast cancer will facilitate targeting miRs for possible therapy. Improper involution possibly contributes towards tumour development. miR-444/442/503 regulates mammary involution in humans by targeting BCL-2 (B-cell lymphoma 2; anti-apoptotic) and IGF1R (insulin like growth factor-1-receptor) genes. The loss of this miR leads to malignancy and nonresponse to chemother-apy, demonstrating its role as a tumour suppressor. By contrast, some miRs, such as miR-660-5p, promote tumour development and metastasis, and the level of miR-660-5p was found to be increased in MCF7 breast cancer cell lines. This miR’s tumour promoting activity was confirmed by observation of reduced invasion of MCF7 cells at reduced miR-660-5p levels.
One of the major causes of breast cancer is disturbed estrogen signaling, where the altered expression of estrogen receptor α (ERα) and its cross-talk with the related miR culminates in neoplasia\(^\text{20}\). Studies on the effect of E2 on the expression pattern of miRs in MCF7 and ZR75 cell lines revealed 172 miRs that were up or downregulated. Notable miRs in tissue are miR-206, miR-34a, miR-17-5p, and miR-125 a/b, which act as tumour suppressors, and miR-21, miR-10B, and miR-155, which act as oncogenes\(^\text{21}\). Another study using an ACI rat model for the effect of E2 on the miR signature showed 33 dysregulated miRs\(^\text{22}\). Additionally, the use of ellagic acid (natural phenol antioxidant) reversed the dysregulation of miR-206, miR-182, miR-375, miR-127, miR-183, and miR-122, subsequently modulating the target proteins ERα, RASD1, cyclin D1, FoxO1, FoxO3a, Bcl-w, Bcl-2 and cyclin G1\(^\text{18}\). Furthermore, overexpression of the tumour suppressing miR-133a in MCF-7 and MDA-MB-231 cells suppressed phosphorylated Akt (p-Akt) protein and inhibited p-Akt nuclear translocation, and this miR also regulates the cell cycle of cancerous cells by targeting the EGFR (epidermal growth factor receptor) gene\(^\text{20}\).

miR-206 is found to play a crucial role in BRCA1 (Breast Cancer susceptibility gene; tumour suppressor) depleted mouse mammary gland\(^\text{23}\). Overexpression of miR-206 showed no effect on lactation, but did have a role in tissue remodeling through increasing fat tissue and reducing branching morphogenesis. There may be a possibility of increased miR-206 levels due to BRCA1 loss, culminating in mammary gland remodeling and tumour development\(^\text{24}\). miR-184 is found to be a tumour suppressor by regulating the number of genes in the PI3K/AKT/mTOR pathway, as observed by miR profiling of the pubertal mouse mammary gland\(^\text{25}\). This pathway is important in mammary gland development and lactation\(^\text{26}\). miR-184 is only expressed in epithelial cells, and the level increases during differentiation of cells from terminal end bud into ductal epithelial cells\(^\text{15}\). The miR 126/126* pair is observed to repress the recruitment of mesenchymal stem cells and inflammatory monocytes into the tumour stroma, thus inhibiting breast cancer metastasis\(^\text{27}\). Urinary miR detection of overexpressed miR-155, and lowered expression of miR – 21, 125b, and 451 can act as non-invasive biomarker for breast cancer detection\(^\text{28}\). Chan et al. (2013)\(^\text{29}\) identified the miR signature (miR-1, 92a, 133a, and 133b) in serum which can be used as biomarkers for breast cancer detection as a noninvasive diagnostic strategy. Similar study by Mar-Aguilar et al., (2013)\(^\text{30}\) identified miR-145, 155, and 382 as potential biomarker for breast cancer detection. Deregulated expression of miR-17, 34a, 155, and 373 and their concentration in serum as cell-free miR probably connects to the progression and metastasis of breast cancer\(^\text{15}\).

Exosomes are cell - derived small vesicles (40 – 100 nm) containing mRNA, protein, miR etc. They are crucial mediator of inter cellular signaling during cancer development. Exosomes derived from cancer associated fibroblasts in breast cancer have 3 miRs such as miR-21, -143, and -378e which promote stemness, epithelial-mesenchymal transition, and anchorage-independent cell growth, thus accelerating oncogenic signaling in breast cancer cells\(^\text{32}\). The exosomes released from cancer cells of breast cancer patients induce the non-tumorigenic epithelial cells to form tumors with the help of dicer endonuclease\(^\text{33}\).

Triple negative breast cancer (TNBC) is a subtype of breast cancer where the cancer cells lack the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2)\(^\text{34}\). Out of total breast cancer cases 10 – 20% are TNBC cases and various studies showed the expression of specific miR pattern in these cases which can act as biomarker for cancer diagnosis\(^\text{35,36}\). A recent study on paired sera and tissue samples of TNBC patients in India revealed overexpression of 3 oncogenic miRs (miR – 21, 221, and 210) and down regulation of miR – 195 and miR – 145 as compared to that of triple positive breast cancer cases. The TNBC cases were found to be highly prevalent (73.9%) in pre-maunopausal (<35 yr) women and the miR let7a was overexpressed although it is known as a tumour suppressor. Increased serum level of exosomal miR-373 can also be a marker for TNBC cases\(^\text{37}\). The study of TNBCs with lymphnode metastases showed association of 27 miRs with metastatic capability. This study observed 71 differentially expressed miRs in TNBCs including miR-200 family and miR-17-92 oncogenic cluster\(^\text{38}\).

**Conclusions**

miRs have been shown to be one of the major regulators of mammary gland development and neoplasia. miRNome studies of mammary gland in different developmental stages and cancerous tissues will elucidate biomarkers for early cancer diagnosis, and may be used as therapeutic targets. Future studies focusing on the cross-talk between miRs and target genes with the imaging pathways involved in development and neoplasia of mammary gland will open the door to understand mammary gland biology and oncogenesis in molecular detail.

**Competing interests**

No competing interests were disclosed.

**Grant information**

The author(s) declared that no grants were involved in supporting this work.
References

1. Gigli I, Maizon DO: microRNAs and the mammalian gland: A new understanding of gene expression. Genet Mol Biol. 2013; 36(4): 465–474. 
2. Jin HY, Xiao C: MicroRNA mechanisms of action: What have we learned from mice? Front Genet. 2015; 6: 328. 
3. Wang CD, Long K, Jin L, et al.: Identification of conserved microRNAs in peripheral blood from giant panda: expression of mammalian gland-related microRNAs during late pregnancy and early lactation. Genet Mol Res. 2015; 14(4): 14216–14224. 
4. Alsaweed M, Lai CT, Hartmann PE, et al.: Human milk miRNAs primarily originate from the mammary gland resulting in unique miRNA profiles of farm vs. city milk. Sci Rep. 2016; 6: 20569. 
5. Modepalli V, Kumar A, Hinds LA, et al.: Differential temporal expression of milk miRNA in normal secretory and de novo lipogenesis. Development. 2016; 143(20): 4236–4248. 
6. Li R, Dudemaine PL, Zhao X, et al.: Comparative Analysis of the miRNAome of Bovine Milk Fat, Whey and Cells. PLoS One. 2016; 11(4): e0154129. 
7. Chu M, Zhao Y, Feng Y, et al.: MiR-126 participates in lipid metabolism in mammary epithelial cells. Mol Cell Endocrinol. 2017; 454: 77–86. pii: S0303-7207(17)30819-0. 
8. Heinz RE, Rudolph MC, Ramanathan P, et al.: Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis. Development. 2016; 143(20): 4236–4248. 
9. Wang H, Shi H, Luo J, et al.: MiR-145 Regulates Lipogenesis in Goat Mammary Gland Cells Via Targeting INSIG1 and Epigenetic Regulation of Lipid-Related Genes. J Cell Physiol. 2017; 232(5): 1000–1040. 
10. Wang H, Luo J, Chen Z, et al.: MiR-24-2 can control triacylglycerol synthesis in goat mammary epithelial cells by targeting the fatty acid synthase gene. J Dairy Sci. 2015; 98(12): 9001–9014. 
11. Murao S, Hagi T, Kimura A, et al.: Lactogenic hormones alter cellular and extracellular miRNA expression in bovine mammary epithelial cell culture. J Anim Sci Biotechnol. 2016; 7: 8. 
12. Bao Y, Lei Y, Wang C, et al.: Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy Cow Mammary Epithelial Cells. J Cell Physiol. 2015; 230(9): 1525–63. 
13. Li D, Xie X, Wang J, et al.: MiR-486 regulates lactation and targets the PTEN gene in cow mammary glands. PLoS One. 2015; 10(3): e0118284. 
14. Sobchak-L, Marthey S, Le Guillou S, et al.: Food Deprivation Affects the miRNAome in the Lactating Goat Mammary Gland. PLoS One. 2015; 10(10): e0140111. 
15. Lin X, Luo J, Zhang L, et al.: MicroRNAs synergistically regulate milk fat synthesis in mammary gland epithelial cells of dairy goats. Gene Expr. 2013; 16(1): 1–13. 
16. Li Z, Liu H, Jin X, et al.: Expression profiles of microRNAs from lactating and non-lactating bovine mammary glands and identification of miRNA related to lactation. BMC Genomics. 2012; 13: 731. 
17. Alsaweed M, Lai CT, Hartmann PE, et al.: Human Milk Cells and Lipids Conserve Numerous Known and Novel miRNAs, Some of Which Are Differentially Expressed during Lactation. PLoS One. 2016; 11(4): e0152610. 
18. Rodriguez-Barureoa R, Nekritz EA, Bertucci F, et al.: mir-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev. 2013; 27(21): 2560–2566. 
19. Shen Y, Ye YF, Ruan LW, et al.: Inhibition of mir-660-5p expression suppresses tumor development and metastasis in human breast cancer. Genet Mol Res. 2017; 16(1): gmr16019470. 
20. Manavathi B, Dey O, Gajulapalli VN, et al.: Detailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev. 2013; 34(1): 1–32. 
21. Ferraro L, Nava M, Nasas G, et al.: Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells. Horm Cancer. 2012; 3(3): 65–78. 
22. Munagala R, Arj F, Vadhvanam MV, et al.: MicroRNA ‘signature’ during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. Cancer Lett. 2013; 339(2): 175–84. 
23. Cui W, Zhang S, Shan C, et al.: miRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J. 2013; 280(16): 3962–74. 
24. Wronski A, Sandhu GK, Milewsky MJ, et al.: MicroRNA-206 is differentially expressed in Brca1-deficient mice and regulates epithelial and stromal cell compartments of the mouse mammary gland. Oncogene. 2016; 35: e218. 
25. Phua YW, Nguyen A, Roden DL, et al.: MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Res. 2015; 17: 83. 
26. Wang Z, Hou X, Qu B, et al.: Pten regulates development and lactation in the mammary glands of dairy cows. PLoS One. 2014; 9(7): e102118. 
27. Zhang Y, Yang P, Sun T, et al.: miR-126 and mir-126-1 repress recruitment of mesenchymal stem cells and inflammatory monocyes to inhibit breast cancer metastasis. Nat Cell Biol. 2013; 15(3): 284–94. 
28. Erbes T, Hirschfeld M, Rücker G, et al.: Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer. 2015; 15: 193. 
29. Chan M, Liew CS, Ji SM, et al.: Identification of circulating microRNA signatures for breast cancer detection and clinical outcome. Breast Cancer Res. 2013; 15(16): 4477–87. 
30. Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, et al.: Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013; 34(9): 163–9. 
31. Eichelseder C, Flesch-Jansy D, Chang-Claude J, et al.: Deregulated serum concentrations of circulating cell-free microRNAs mir-17, mir-34a, mir-155, and mir-373 in human breast cancer development and progression. Clin Chem. 2013; 59(10): 1489–96. 
32. Donnanna EM, Fiore D, Nappa M, et al.: Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017; 8(12): 19692–19608. 
33. Mellin J, Boeckx C, Nijs S, et al.: Identification of Specific miRNA Signature for Breast Cancer with Improved Prognostic Value. Cancers (Basel). 2016; 8(4): e165. 
34. Yang Q, Liu HY, Liu D, et al.: Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes. Asian Pac J Cancer Prev. 2014; 15(9): 3229–32. 
35. Medineh I, Ommare I, Privat M, et al.: MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. PLoS One. 2014; 9(11): e111877. 
36. Thakur S, Grover RK, Gupta S, et al.: Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer. PLoS One. 2016; 11(7): e0158446. 
37. Eichelseder C, Stückroth I, Müller V, et al.: Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014; 5(30): 9650–63. 
38. Averee-Kipka KA, Braye SG, Mathe A, et al.: Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC cancer. 2014; 14(1): 51.
Open Peer Review

Current Referee Status:  

Mohammed Alsaweed
College of Applied Medical Sciences, Majmaah University, Al Majma’ah, Saudi Arabia

All the suggestions made by the referee are sufficient and the paper is suggested to be indexed in F1000Research.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Bhudev C. Das
Molecular Oncology Laboratory, B.R. Ambedkar Centre for Biomedical Research (ACBR), University of Delhi, New Delhi, India

Review article on "MicroRNAs in the development and neoplasia of the mammary gland" submitted by M.K. Jena deals with how various microRNAs that regulate gene expression through post transcriptional gene silencing are important during development and progression as well as prognosis of cancer of the mammary gland in women. Though I understand it is a mini-review but it has not been written in a very focused and systematic way. There are huge numbers of publications in this field, particularly the role of mRNA in breast carcinogenesis. However, the author cites only 22 references in this article which is highly inadequate to justify the review on the role of miRNA in mammary gland development and carcinogenesis. Author must consult recently published literatures including a recent paper by Thakur et al. (2016) and many of the references therein. There are a lot of sweeping comments have been made which indicates that the author has nothing much to do with cancer specialty. The comments in abstract say 'miRs are responsible for breast cancer development'. It is not straight forward and clear that miRNA are responsible of breast cancer development. They may be associated with but not directly correlated with cancer development. Similar sweeping comments are many in the text and these need to be addressed properly and the manuscript needs to be elaborative and focused. The presentation of the
review article should be made with proper sub-headings on mammary gland development, lactation and carcinogenesis.

In summary, I suggest that the article can be considered for indexing only after satisfactory revision.

References
1. Thakur S, Grover RK, Gupta S, Yadav AK, Das BC: Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer. PLoS One. 2016; 11 (7): e0158946 PubMed Abstract I Publisher Full Text

Is the topic of the review discussed comprehensively in the context of the current literature?
Yes

Are all factual statements correct and adequately supported by citations?
Partly

Is the review written in accessible language?
Partly

Are the conclusions drawn appropriate in the context of the current research literature?
Partly

Competing Interests: No competing interests were disclosed.

Referee Expertise: Molecular oncologist

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 01 Oct 2017
Manoj Jena, Lovely Professional University, India

All the suggestions made by the referee has been complied in the second version of this article.

Competing Interests: No competing interests were disclosed.

Referee Report 19 September 2017
doi:10.5256/f1000research.12984.r25931

Shantibhusan Senapati
Tumor Microenvironment and Animal Models Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India

With this review, the author provide a concise literature summary of microRNAs in the development and neoplasia of the mammary gland. For the most part the review is complete and informative. To further improve the quality, the author is advised to address these minor points:
1. Exosomes secreted by different cells of mammary gland carry microRNA. It has been demonstrated that cancer-associated fibroblasts release exosomal microRNA that induce aggressiveness in breast cancer cells (e.g. Donnarumma et al. (2017)\(^1\)). At the same time, the microRNA present in the exosomes secreted by the cancer cells also play a critical role in the pathogenesis of breast cancer (e.g. Melo et al. (2014)\(^2\)). Hence, the authors might consider to include these information.

2. The beginning sentence under “miRs in mammary gland” heading needs to be restructured. The presence of miRNA in milk and the role of miRNA in mammary development should be mentioned separately.

3. In the abstract, the sentence “Further studies in this area will help us understand ……” should be “Further studies in this area will help us to understand …….”)

References
1. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C, Rienzo A, Piscuoglio S, Thomas R, Condorelli G: Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017; 8 (12): 19592-19608 PubMed Abstract | Publisher Full Text
2. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R: Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014; 26 (5): 707-21 PubMed Abstract | Publisher Full Text

Is the topic of the review discussed comprehensively in the context of the current literature? Yes

Are all factual statements correct and adequately supported by citations? Yes

Is the review written in accessible language? Yes

Are the conclusions drawn appropriate in the context of the current research literature? Yes

Competing Interests: No competing interests were disclosed.

Referee Expertise: Tumor microenvironment, animal models, stroma and cancer cell crosstalk

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 22 Sep 2017
Manoj Jena, Lovely Professional University, India
To be incorporated in the heading "miRs controlling involution and breast cancer": Exosomes are cell-derived small vesicles (40-100 nm) containing mRNA, protein, miR etc. They are crucial mediator of inter cellular signaling during cancer development. Exosomes derived from cancer associated fibroblasts in breast cancer have 3 miRs such as miR-21, -143, and -378e which promote stemness, epithelial-mesenchymal transition, and anchorage-independent cell growth, thus accelerating oncogenic signaling in breast cancer cells (Donnarumma et al., 2017). The exosomes released from cancer cells of breast cancer patients induce the non-tumorigenic epithelial cells to form tumors with the help of dicer endonuclease (Melo et al., 2014).

The beginning sentence under “miRs in mammary gland” will be restructured. The presence of miRNA in milk and the role of miRNA in mammary development will be separated.

In the abstract, the sentence “Further studies in this area will help us understand ……” will be rectified as “Further studies in this area will help us to understand …….”

**Competing Interests:** No competing interests were disclosed.
Zhang et al. (2013, Nature Cell Biology) has provided breast cancer inhibits progression by microRNAs expression roles, so it must be considered in this review.

Is the topic of the review discussed comprehensively in the context of the current literature?
Yes

Are all factual statements correct and adequately supported by citations?
Yes

Is the review written in accessible language?
Yes

Are the conclusions drawn appropriate in the context of the current research literature?
Yes

Competing Interests: No competing interests were disclosed.

Referee Expertise: microRNA, gene expression regulation, lactation, mammary gland, milk, human milk

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 09 Aug 2017

Manoj Jena, Lovely Professional University, India

Introduction
Mechanism of action to be incorporated: Matured miRs integrate into the RNA - induced silencing complex (RISC) and direct it to target mRNAs through partial sequence complementarity. miRs down regulate the target gene expression by translation repression (48 % through RISC complex), or mRNA degradation (29 %), or by both phenomena (23 %). (Jin and Xiao, 2015).

miRs in mammary glands
To be removed: The role of miRs........still disputed.
To be incorporated: miRs in milk during lactation are putative markers of activities in mammary gland and act as functional signals for proper growth and development of the young. The highly abundant miRs in milk during lactation cycle are miR-191, 184, 181, 148, 375, and miRs of let-7 family (7f, 7a and 7i) as evidenced from studies in the marsupial tammar wallaby (Modepalli et al., 2014).

miRs controlling lactation
To be incorporated: Lin et al (2013) observed group of miRs (such as miR-23a, 27b, 103, and 200a) affect milk fat synthesis with synergistic action. miR profiling of lactating and nonlactating bovine mammary gland revealed miR-125b, 181a, and 199b expression level reduced in non-lactation period; whereas miR-141, 484, and 500 expression level was higher in lactation period. (Li et al., 2012). Highly expressed miRs such as let-7f-5p is found to target many genes involved in protein, carbohydrate, and triglyceride synthesis. The human milk enriched miR such as miR-22-3P regulates development and differentiation of T-lymphocytes. The miR-181a-5p and miR-182-5p have crucial role in immune cell differentiation, miR-375 is required for glucose
homeostasis, and miR-148a-3p is a tumour suppressor and involved in liver development (Alsaweed et al., 2016).

**miRs controlling involution and breast cancer**
To be incorporated: The miR 126/126* pair is observed to repress the recruitment of mesenchymal stem cells and inflammatory monocytes into the tumour stroma, thus inhibiting breast cancer metastasis (Zhang et al., 2013).

**Competing Interests:** No competing interests were disclosed.